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Introduction 
Conclusions 
We hypothesized that acute hyperglycemia (200 mg/dL) would increase blood 
H2O2 levels and decrease blood NO levels compared to saline control. By inhibiting 
NOX1 using ML171(2-acetylphenothiazine, MW=241.31 g/mol, Tocris 
Bioscience), acute hyperglycemia-induced vascular dysfunction would be 
attenuated.  This will be noted by decreased blood H2O2 levels and increased blood 
NO levels compared to acute hyperglycemia control. 
 
 
Our results indicate that NOX1 activation is a key mechanism contributing to acute 
hyperglycemia-induced oxidative stress and NO reduction in vascular tissue.  
Furthermore, inhibition of NOX1 may mitigate the deleterious effects of acute 
hyperglycemia. The outcomes from this study suggest that ML171 may be a 
therapeutic tool to attenuate vascular dysfunction associated with diabetic patients. 
  
Male Sprague-Dawley rats (275-325g; Charles River, Springfield, MA) were 
anesthetized and subsequently infused with saline, 30% glucose, or 30% glucose 
with 20 µg/Kg or 100 µg/Kg ML171 (approximately 1 or 5 µM in blood) via the 
cannulation of jugular vein. Hyperglycemic conditions (≥200 mg/dL) were 
induced, maintained, and monitored as previously described [4]. Mean arterial 
blood pressure (MABP) was monitored through catheterization of the carotid 
artery.  Blood NO and H2O2 levels were measured in real time by NO or H2O2 
microsensors as previously described (see figure 3) [4]. All data in the figures are 
presented as means ± S.E.M. The data were analyzed by ANOVA using the 
Student- Newman- Keuls post hoc test, p<0.05 were considered to be statistically 
significant.  
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Chronic hyperglycemia is a major condition of diabetes and it leads to vascular 
complications in diabetic patients.  In non-diabetic patients, acute hyperglycemia 
also results in decreased wound healing and immune function, increased 
myocardial infarction size post myocardial infarction,  and mortality.  These effects 
of hyperglycemia are initiated by vascular endothelial dysfunction which is 
characterized by increased levels of reactive oxygen species (ROS) and decreased 
levels of endothelial-derived nitric oxide (NO).  Endothelial NO synthase (eNOS) 
produces NO and is responsible for maintaining an anti-inflammatory surface to 
facilitate blood flow. NADPH oxidases are a principle source of superoxide (SO) 
during inflammation [1].  SO can directly quench NO by forming peroxynitrite 
which induces eNOS uncoupling and additional ROS release (see figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
SO is rapidly converted to H2O2, which can be measured in blood due to its 
relatively longer half-life (i.e., minutes vs seconds).  There are 7 isoforms of 
NADPH oxidase (NOX) in mammals.  Of these isoforms, NOX1 and NOX2 are 
mainly expressed in vascular endothelial cells and smooth muscle cells [2].  
Previously, we have shown that gp91ds-tat, a NOX2 inhibitor, partially reduced 
blood H2O2 levels induced by hyperglycemic conditions [1].  However, the role of 
NOX1 in hyperglycemia induced oxidative stress and vascular endothelial 
dysfunction is still unclear.  In this study, 2-acetylphenothiazine (ML171), a 
specific inhibitor for NOX1, was used to determine the role of NOX1 in 
hyperglycemia-induced vascular endothelial dysfunction by measuring blood NO 
and H2O2 levels in real-time (see figure 2) [3].  
 
Figure 2. Structure of NADPH Oxidase Isoform 1 (NOX1) and its selective inhibitor, ML171.  
 
Figure 3. Nitric oxide and hydrogen peroxide sensors in the femoral veins. Figure 1. The possible roles of NADPH oxidase and eNOS uncoupling in hyperglycemia-induced vascular 
endothelial dysfunction.   
 
Figure 6. Comparison of blood NO levels relative to saline among 30% D-glucose, 30% D-glucose with 1μM 
ML171,  and 30% D-glucose with 5μM ML171(*p<0.05, **p<0.01 vs Glucose). Hyperglycemia significantly 
reduced blood NO levels  (101.41±10.91 nM, n=8). ML171 (1 and 5 μM) attenuated the hyperglycemia induced 
decrease in blood NO levels and increased blood NO levels by 68.48±12.67 nM (P<0.01, n=5) and 85.95±8.13 nM 
(P<0.01, n=5) respectively at 180 min.. Saline showed no change throughout the experiment.  
Figure  4. Blood glucose changes throughout 180 minute experiment with 30% D-glucose. Blood 
glucose levels were maintained at ~200 mg/dL in all study groups except for saline. 
Figure 7. Comparison of blood H2O2 levels relative to saline among 30% D-glucose, 30% D-glucose with 1μM 
ML171,  and 30% D-glucose with 5μM ML171(*p<0.05, **p<0.01 vs Glucose). Hyperglycemia significantly 
increased blood H2O2 levels by 3 ± 0.42 μM (n =9).  ML171 (1 and 5 μM) significantly decreased blood H2O2 levels 
by 1.86 ± 0.61 μM (n=8) and 4.85 ± 1.02 μM (n=5) respectively at 180 min. Saline showed no change throughout the 
experiment. 
Figure 5. Mean Arterial Blood Pressure among groups taken every 20 minutes for 180 minute experiment. MABP 
was maintained between 100-120 mmHg in all study groups.  
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